Hepatology

The modified difference-in-differences analysis found notable increases in DAA use after state Medicaid programs relaxed certain coverage restrictions.

Although overall engagement in the HCV care cascade improved after the introduction of DAAs, vulnerable subgroups still received less testing and treatment.

Results showed poorly controlled HbA1C increased the risk of elevated ALT levels in children and adolescents with type 1 diabetes, suggesting an important link to MASLD.

HBV DNA and HBsAg were not significantly associated with NAFLD in patients with treatment-naïve HBV, but age, BMI, comorbidities, and certain metabolic laboratory parameters were.

Madrigal Pharmaceuticals announced resmetirom is available in the US beginning on April 9, 2024, ushering in a new era of NASH management.

An analysis of NHANES data found no significant association between HCV infection and risk of prostate cancer, contrary to findings from previous research.

Results highlight increased safety and efficacy of curative HCV therapy among reproductive-age female patients compared with males, potentially preventing vertical infection transmission.

The 2024 HBV guidelines provide updated evidence-informed recommendations on key priority topics including treatment eligibility, diagnostics, and service delivery.

Participants who received facilitated telemedicine initiated DAA therapy faster and had greater cure rates than those who were referred to an off-site hepatitis specialist.

Our March 2024 hepatology month in review highlights HCPLive’s coverage of the FDA approval of resmetirom for MASH/NASH and other key hepatic pipeline news.

SZN-043 showed evidence of target engagement, Wnt signal activation, and effects on liver function, supporting its advancement to a phase 1b trial in severe alcohol-associated hepatitis.

Topline results at week 52 show LPCN 1148 treatment met both the primary and hepatic encephalopathy endpoints in the management of cirrhosis.

New data suggest adding fibrate therapy to frontline PBC treatment could result in earlier and higher rates of biochemical response.

The first-in-human trial of VRON-0200, a novel immunotherapy for chronic hepatitis B virus, presented at the APSAL meeting, demonstrates a promising safety and tolerability profile.

Patients with cirrhosis had greater health care costs than matched controls, attributed mostly to cirrhosis complications and high inpatient utilization in the first year after diagnosis.

The phase 2, proof-of-concept LEGEND trial achieved its primary efficacy endpoint for absolute reduction in HbA1c at week 24 with lanifibranor alone or in combination with empagliflozin.

A recent survey found telemedicine-based HCV treatment at a syringe access program could improve access to treatment among people who inject drugs.

In the final installment in our 5-part video series, our pair of experts in hepatology touch upon how an approval for MASH would impact conversations around screening for asymptomatic patient populations.

Test your knowledge of the 2023 American Association for the Study of Liver Diseases/Infectious Diseases Society of America HCV guideline!

Curtis discusses findings from her recent health economic study about the cost-effectiveness of treating perinatal HCV earlier, a growing concern amid rising rates of HCV in reproductive-aged adults.

In a landmark decision, the FDA has granted accelerated approval to resmetirom (Rezdiffra) for noncirrhotic NASH with moderate to advanced fibrosis.

To acknowledge World Kidney Day, our latest episode of Crisis Point focuses on the stigma surrounding the use of HCV-positive donor kidneys amid the ongoing organ shortage crisis, with the perspective of a pair of experts and an HCV donor kidney recipient.

Saeed Mohammed, MD, MS, discusses maralixibat for pruritus in PFIC, describing how IBAT inhibitors have changed the way clinicians are able to treat cholestatic liver disease.

Treatment with DAA therapy at 3 years of age was associated with better health outcomes and cost savings versus deferring initiation to 6 years of age or older.

The phase 3 ENLIGHTEN program will consist of 2 phase 3 trials evaluating the safety and efficacy of pegozafermin in patients with MASH.

Curative DAA therapy did not completely normalize immune activation and inflammatory biomarkers in individuals with a history of injection drug use and HCV infection.

Although abstinence is the safest approach, patients with SLD at low risk for advanced fibrosis can safely consume < 7.4 g/day of alcohol, equivalent to half of a standard US drinking unit.

Seropositivity was associated with greater albuminuria but not peripheral artery disease in a cohort of patients ≥ 50 years of age with type 2 diabetes mellitus.

Our February 2024 month in review highlights some of our top hepatology content from the past few weeks, including pipeline updates, phase 2/3 trial data, and new research in liver diseases.

Results showed 95.8% of patients who were treated for HCV with DAA therapy and underwent renal transplantation did not experience HCV recurrence.